Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering agents that significantly improve the prognosis of patients with type 2 diabetes (T2D) and heart failure. SGLT2i has recently been implicated in the treatment of atrial fibrillation (AF) with clinical data demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xiaodong, Li, Linling, Zhang, Mengxia, Zhao, Qianqian, Wu, Kui, Bai, Rong, Ruan, Yanfei, Liu, Nian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417344/
https://www.ncbi.nlm.nih.gov/pubmed/32848857
http://dx.doi.org/10.3389/fphys.2020.00912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417344/
https://www.ncbi.nlm.nih.gov/pubmed/32848857
http://dx.doi.org/10.3389/fphys.2020.00912

Ejemplares similares